Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Chronic hepatitis C infection (CHC) is acknowledged as a major health problem all over the world. The World Health Organization estimates that 3-4 million individuals are infected each year worldwide, with a global 170 million chronic HCV carriers at risk of developing liver cirrhosis and/or liver cancer. The most experienced treatment for chronic hepatitis C is pegylated interferon (PEGINF) and ribavirin (RBV) combination therapy. A variety of conditions ranging from endocrinopathies to different skin diseases have been described in only HCV infections and/or associated with IFN based therapy.